In the BioHarmony Drug Report Database

"Preview" Icon

Bexarotene

Targretin (bexarotene) is a small molecule pharmaceutical. Bexarotene was first approved as Targretin on 1999-12-29. It is used to treat t-cell lymphoma cutaneous in the USA. It has been approved in Europe to treat t-cell lymphoma cutaneous. The pharmaceutical is active against retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-alpha, and retinoic acid receptor RXR-beta. In addition, it is known to target peroxisome proliferator-activated receptor gamma.

 

Trade Name

 

Targretin
 

Common Name

 

bexarotene
 

ChEMBL ID

 

CHEMBL1023
 

Indication

 

t-cell lymphoma cutaneous
 

Drug Class

 

Arotinoid derivatives

Image (chem structure or protein)

Bexarotene structure rendering